Andrographolide Attenuates NLRP3 Inflammasome Activation and Airway Inflammation in Exacerbation of Chronic Obstructive Pulmonary Disease
Yan Yu,Ti-wei Miao,Wei Xiao,Bing Mao,Long-yi Du,Yan Wang,Juan-juan Fu
DOI: https://doi.org/10.2147/dddt.s445788
IF: 4.3188
2024-05-25
Drug Design Development and Therapy
Abstract:Yan Yu, 1, &ast Ti-wei Miao, 1, &ast Wei Xiao, 1 Bing Mao, 1 Long-yi Du, 1 Yan Wang, 2 Juan-juan Fu 1 1 Division of Pulmonary Medicine, Department of Internal Medicine, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China; 2 Research Core Facility, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China &astThese authors contributed equally to this work Correspondence: Juan-juan Fu, Division of Pulmonary Medicine, Department of Internal Medicine, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, 37 Guoxue Street, Chengdu, Sichuan, 610041, People's Republic of China, Tel +86-18980606822, Email Purpose: The aim of this study is to uncover the anti-inflammatory propertity of andrographolide (AGP) in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and the underlying mechanisms related to the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome pathway. Methods: An in vivo experiment was conducted on murine model of AECOPD through endotracheal atomization of elastase and lipopolysaccharide (LPS). Intraperitoneal AGP was administered four times. NLRP3 inflammasome pathway molecules were examined using real-time quantitative polymerase chain reaction (RT-qPCR) and Western blot analysis. By using enzyme-linked immunosorbent assay (ELISA), we tested interleukin (IL)-1β levels in bronchoalveolar lavage fluid. An in vitro study was conducted to determine how AGP impacts the NLRP3 inflammasome in THP-1 derived macrophages. The levels of molecules involved in the pathway were measured. Furthermore, molecular docking analyses were carried out to investigate the interactions between AGP and pathway targets. Results: In the in vivo study, NLRP3 inflammasome activation was observed in mice experiencing AECOPD. The administration of high-dose AGP demonstrated a mitigating effect on inflammatory cells infiltration in the lungs. Moreover, AGP administration effectively suppressed the expression of NLRP3, apoptosis associated speck-like protein that contains a CARD (PYCARD), cysteinyl aspartate-specific protease-1 (Caspase-1), IL-1β, and IL-18 at both the genetic and protein levels. In the in vitro experiment, IL-1β levels were significantly elevated in THP-1 derived macrophages with activated inflammasome compared to the control group. Furthermore, the downregulation of NLRP3, CASP1, and IL1B genes was observed upon the inhibition of NLRP3 expression through small interfering RNA (siRNA). AGP demonstrated inhibitory effects on the gene expression and protein levels of NLRP3, Caspase-1, and IL-1β. Additionally, molecular docking analysis confirmed that AGP exhibited a favorable binding affinity with all five targets of the pathway. Conclusion: AGP effectively inhibited NLRP3 inflammasome activation and mitigated the inflammatory reaction of AECOPD both in animal models and in vitro experiments, highlighting the potential of AGP as a treatment for AECOPD with anti-inflammatory properties. Keywords: andrographolide, NLRP3 inflammasome, IL-1β, chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) is a global public health issue that is characterized by chronic respiratory symptoms (dyspnea, cough, and sputum production), persistent airway inflammation and airflow limitation. 1,2 According to findings from the China Pulmonary Health (CPH) study, individuals with spirometry-defined COPD in China are estimated to be 99.9 million, representing approximately 8.6% of the total population. 3 Moreover, according to the World Health Organization, COPD accounts for approximately 3 million deaths in 2019, making it the third most prevalent cause for death globally. 4 Patients with COPD occasionally experience sudden worsening in airway function and respiratory symptoms, known as acute exacerbation of COPD (AECOPD). 5 AECOPD has significant adverse consequences for patients, including poorer health status, expedited deterioration in lung capacity, faster disease progression, and increased mortality rates. 6–8 Aggravated airway and systemic inflammatory responses are hallmarks of AECOPD. Systemic corticosteroids are extensively utilized in the management of AECOPD due to their effectiveness in suppressing airway inflammation. 9 Nonetheless, the use of these medications is accompanied by various adverse effects, such as increased susceptibility to infections, hyperglycemia, and gastrointest -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal